# Sustained Release Formulation of Somatropin (rDNA Origin)for Injection

> **NCT00600808** · PHASE2,PHASE3 · COMPLETED · sponsor: **BioPartners GmbH** · enrollment: 51 (actual)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** BPLG-003

## Key facts

- **NCT ID:** NCT00600808
- **Lead sponsor:** BioPartners GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2008-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600808, "Sustained Release Formulation of Somatropin (rDNA Origin)for Injection". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00600808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*